Severe flare-up in a prostate cancer patient treated with luteinizing hormone-releasing hormone analogue depot

A 65-year-old man with advanced prostate cancer was treated with a luteinizing hormone-releasing hormone (LH-RH) analogue. Four days after the initial injection of 3.6 mg of goserelin acetate, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up. Ches...

Full description

Saved in:
Bibliographic Details
Published inHinyokika kiyo. Acta urologica Japonica Vol. 39; no. 10; p. 953
Main Authors Shimizu, T, Shibata, Y, Uchida, T, Satoh, J
Format Journal Article
LanguageEnglish
Published Japan 01.10.1993
Subjects
Adenocarcinoma - drug therapy
Adenocarcinoma - pathology
Aged
Drainage
Goserelin - adverse effects
Humans
Lung Neoplasms - secondary
Lymphatic Metastasis
Male
Pleural Effusion, Malignant - chemically induced
Pleural Effusion, Malignant - therapy
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Online AccessGet full text

Cover

More Information
Summary:A 65-year-old man with advanced prostate cancer was treated with a luteinizing hormone-releasing hormone (LH-RH) analogue. Four days after the initial injection of 3.6 mg of goserelin acetate, severe dyspnea developed due to worsening pleuritis carcinomatosa, which was considered as a flare-up. Chest drainage was required to save his life. Therefore, we emphasize the importance of treatment to prevent tumor flare during LH-RH analogue therapy.
ISSN:0018-1994